Reuters logo
6 months ago
BRIEF-ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet
March 2, 2017 / 6:02 AM / 6 months ago

BRIEF-ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet

March 2 (Reuters) - ALK-Abello A/S:

* Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe)

* Approval of the HDM SLIT-tablet is not expected to have an impact on ALK's 2017 financial outlook

* CEO says "approval of the HDM SLIT-tablet marks the beginning of a new era for ALK in the USA as we now take full control of the SLIT-tablet portfolio and integrate it into our existing US business" Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below